Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13765-13781

  Zeng, Dong Qiang ^a,b   Yu, Yun Fang ^a   Ou, Qi Yun ^a,c   Li, Xiao Yin ^b   Zhong, Ru Zhi ^d   Xie, Chuan Miao ^c   Hu, Qiu Gen ^a  

^a SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Molecular subtypes; Non small cell lung cancer; Survival; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE SPECIFIC SURVIVAL; HAZARD RATIO; HUMAN; LYMPH NODE METASTASIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TUMOR ASSOCIATED LEUKOCYTE; IMMUNOLOGY; LUNG TUMOR; META ANALYSIS (TOPIC); PATHOLOGY; PROGNOSIS; THERAPEUTIC RESEARCH;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; META-ANALYSIS AS TOPIC; PROGNOSIS; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 84971665322     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7282     Document Type: Article

References (55)

1. Fridman WH, Pages F, Sautes-Fridman C and Galon J. The immune contexture in human tumours: impact on clinical outcome. Nature reviews Cancer. 2012; 12:298-306.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012; 12:252-264.
3. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature medicine. 2007; 13:1050-1059.
4. Zitvogel L, Kepp O and Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature reviews Clinical oncology. 2011; 8:151-160.
5. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England journal of medicine. 2005; 353:2654-2666.
6. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH and Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27:5944-5951.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY). 2006; 313:1960-1964.
8. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C and Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29:1093-1102.
9. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA and Badve SS. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014; 32:2959-2966.
10. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer research. 2011; 71:5670-5677.
11. Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X and Hou J. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer immunology, immunotherapy : CII. 2012; 61:1849-1856.
12. Detterbeck FC, Postmus PE and Tanoue LT. The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143:e191S-210S.
13. Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M and Adusumilli PS. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31:490-498.
14. Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y and Ouyang X. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical lung cancer. 2015.
15. Kim MY, Koh J, Kim S, Go H, Jeon YK and Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015; 88:24-33.
16. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S and Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. British Journal of Cancer. 2006; 94:275-280.
17. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H and Nishimura M. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007; 98:1424-30.
18. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S and Ochiai A. Predominant infiltration of macrophages and CD8 (+) T Cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer. 2008;113:1387-95.
19. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H and Nishimura M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Science. 2003; 94:1003-1009.
20. Ikeda S, Funakoshi N, Inagaki M and Shibata T. Clinicopathologic roles of tumor-infiltrating lymphocytes and CD8-positive lymphocytes in lung cancer imprint smears in squamous cell carcinoma and adenocarcinoma Acta Cytologica. 2006; 50:423-429.
21. Petersen RP, Carnpa MJ, Sperlazza J, Conlon D, Joshi M-B, Harpole DH, Jr. and Patz EF, Jr. Tumor infiltrating FOXP3(+) regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients. Cancer. 2006; 107:2866-2872.
22. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM and Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical Cancer Research. 2008; 14:5220-5227.
23. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S and Ochiai A. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113:1387-1395.
24. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, Daniele L and Oliaro A. Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms. Annals of Thoracic Surgery. 2009; 87:365-372.
25. Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM and Busund LT. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS. 2010; 118:371-382.
26. Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, Ma J, Ma L and You Z. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer. 2010; 10.
27. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A and Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. Journal of Thoracic Oncology. 2010; 5:585-590.
28. da Costa Souza P, Parra ER, Atanazio MJ, da Silva OB, Noleto GS, Ab'saber AM, de Morais Fernezlian S, Takagaki T and Capelozzi VL. Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma. Histopathology. 2012; 61:587-596.
29. Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C, Mouroux J and Hofman P. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2012; 118:1726-1737.
30. Kayser G, Schulte-Uentrop L, Sienel W, Werner M, Fisch P, Passlick B, Zur Hausen A and Stremmel C. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. Lung Cancer. 2012; 76:445-451.
31. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K and Ueoka H. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012; 75:95-101.
32. Hald SM, Bremnes RM, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Busund LT and Donnem T. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer. 2013; 80:209-215.
33. Hasegawa T, Suzuki H, Yamaura T, Muto S, Okabe N, Osugi J, Hoshino M, Higuchi M, Ise K and Gotoh M. Prognostic value of peripheral and local forkhead box p3+ regulatory T cells in patients with non-small-cell lung cancer. Molecular and Clinical Oncology. 2014; 2:685-694.
34. Tao H, Shien K, Soh J, Matsuda E, Toyooka S, Okabe K and Miyoshi S. Density of Tumor-Infiltrating FOXP3+T Cells as a Response Marker for Induction Chemoradiotherapy and a Potential Prognostic Factor in Patients Treated with Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Annals of Thoracic and Cardiovascular Surgery. 2014; 20:980-986.
35. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, Validire P, Besse B and Mami-Chouaib F. CD8+CD103+ Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patient. Journal of immunology (Baltimore, Md : 1950). 2015; 194:3475-3486.
36. Donnem TP, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland AP, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli KI, Kiselev Y, Sandanger TM, et al. Stromal CD8+ T Cell Density - A Promising Supplement to TNM staging in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015.
37. Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS and Rimm DL. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015; 107.
38. Tian C, Lu S, Fan Q, Zhang W, Jiao S, Zhao X, Wu Z, Sun L and Wang L. Prognostic Significance of Tumor-infiltrating CD8(+) or CD3(+) T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer. Chinese Medical Journal. 2015; 128:105-110.
39. Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, Nason KS, Landreneau RJ, Luketich JD and Schuchert MJ. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. The Journal of surgical research. 2011; 171:1-5.
40. Kilic A, Landreneau RJ, Luketich JD, Pennathur A and Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. The Journal of surgical research. 2011; 167:207-210.
41. Nishikawa H and Sakaguchi S. Regulatory T cells in tumor immunity. International journal of cancer Journal international du cancer. 2010; 127:759-767.
42. deLeeuw RJ, Kost SE, Kakal JA and Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18:3022-3029.
43. Nishikawa H, Jager E, Ritter G, Old LJ and Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005; 106:1008-1011.
44. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366:2443-2454.
45. Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A and Soria JC. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014; 9:144-153.
46. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65:5-29.
47. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009; 339:b2700.
48. Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16.
49. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine. 1998; 17:2815-2834.
50. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003; 327:557-560.
51. DerSimonian R and Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7:177-188.
52. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959; 22:719-748.
53. Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of clinical epidemiology. 2008; 61:991-996.
54. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101.
55. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315:629-634.